Vergent Bioscience's Abenacianine Improves Lung Cancer Tumor Visualization in Phase 2B Trial

Vergent Bioscience announced positive Phase 2B VISUALIZE trial results for abenacianine (VGT-309), a tumor-targeted fluorescent imaging agent. The tr...
Home/KnloSights/Clinical Trial Updates/Vergent Bioscience's Abenacianine Improves Lung Cancer Tumor Visualization in Phase 2B Trial